TherapeuticsMD, Inc. — Director's Dealing 2023

Jan 25, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2023-01-23

Reporting Person: Donegan Michael C (Prin. Fin. and Acctg. Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-23	Common Stock	M	380	$0.00	Acquired	4934	Direct
2023-01-23	Common Stock	M	1066	$0.00	Acquired	6000	Direct
2023-01-23	Common Stock	M	519	$0.00	Acquired	6519	Direct
2023-01-23	Common Stock	M	2400	$0.00	Acquired	8919	Direct
2023-01-23	Common Stock	S	1302	$5.3383	Disposed	7617	Direct
2023-01-24	Common Stock	S	7	$5.3101	Disposed	7610	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-23	Restricted Stock Units	$0.00	M	380	Disposed		Common Stock (380)	Direct
2023-01-23	Restricted Stock Units	$0.00	M	1066	Disposed		Common Stock (1066)	Direct
2023-01-23	Restricted Stock Units	$0.00	M	519	Disposed		Common Stock (519)	Direct
2023-01-23	Restricted Stock Units	$0.00	M	2400	Disposed		Common Stock (2400)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 23, 2023, the reporting person received 4,365 shares of issuer common stock in settlement of restricted stock units (RSUs).

F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of ranging from $5.32 through $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.

F4: The RSUs were to vest in three equal installments annually beginning March 30, 2021 and becoming fully vested on March 30, 2023. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F5: The RSUs were to vest in three equal installments annually beginning July 1, 2022 and becoming fully vested on July 1, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F6: Subject to the reporting person's continuous service, the RSUs were to vest in three equal installments annually, beginning September 29, 2022 and becoming fully vested on September 29, 2024. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".

F7: The RSUs were to vest in three equal installments annually beginning March 23, 2023 and becoming fully vested on March 23, 2025. Vesting was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".